Database : MEDLINE
Search on : Stomatitis [Words]
References found : 22976 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2298 go to page                         

  1 / 22976 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29188398
[Au] Autor:Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
[Ad] Address:Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, No. 33 Yinfeng Road, Haizhu District, Guangzhou, Guangdong, 510288, People's Republic of China.
[Ti] Title:Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
[So] Source:Breast Cancer Res Treat;168(2):337-348, 2018 Apr.
[Is] ISSN:1573-7217
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:PURPOSE: To investigate the efficacy and safety of doublet versus single-agent chemotherapy (CT) plus trastuzumab (H) as first-line therapy for human epidermal growth factor 2 receptor (HER2)-positive metastatic breast cancer (MBC). METHODS: We searched for randomized clinical trials (RCTs) that evaluated the treatment effects of single-agent or doublet CT+H as first-line therapies for HER2-positive MBC. The main outcomes measured for this study included the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). A meta-analysis and trial sequential analysis (TSA) were performed, and the study quality was evaluated using the GRADE framework. The PROSPERO registry number of our analysis is CRD42016043766. RESULTS: The results from four RCTs including 1044 participants were pooled. Moderate-quality evidence indicated that compared with single-agent CT+H, doublet CT+H correlated better with prolonged PFS (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.63-0.75, P < 0.0001) and OS (HR = 0.90, 95% CI 0.88-0.92, P < 0.0001). However, moderate-quality evidence revealed no significant difference between the two regimens regarding the ORR (relative risk [RR] = 1.07, 95% CI 0.98-1.17, P = 0.157), which was confirmed by TSA, indicating that the cumulative Z-curve entered the futility area. Moderate-quality evidence indicated that treatment-related grade 3 or 4 toxicities of thrombocytopenia (RR = 4.08, P = 0.000), nausea/vomiting (RR = 4.26, P = 0.002), diarrhea (RR = 2.81, P = 0.002), and stomatitis (RR = 5.02, P = 0.003) were observed more frequently with doublet CT+H than with single-agent CT+H. CONCLUSIONS: Compared with single-agent CT, the combination of doublet CT with trastuzumab as first-line therapy for HER2-positive MBC is associated with longer PFS and OS, but more treatment-related grade 3 or 4 toxicities. Therefore, doublet CT appears to be an appropriate regimen for HER2-positive MBC with a good performance status.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1007/s10549-017-4592-y

  2 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523624
[Au] Autor:Singh H; Walker AJ; Amiri-Kordestani L; Cheng J; Tang S; Balcazar P; Barnett-Ringgold K; Palmby TR; Cao X; Zheng N; Liu Q; Yu J; Pierce WF; Daniels SR; Sridhara R; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
[Ad] Address:Office of Hematology Oncology Products (OHOP), Division of Oncology Products 1 (DOP1), U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Harpreet.Singh@fda.hhs.gov.
[Ti] Title:U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.
[So] Source:Clin Cancer Res;, 2018 Mar 09.
[Is] ISSN:1078-0432
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:On July 17, 2017, the Food and Drug Administration (FDA) approved neratinib (NERLYNX, Puma Biotechnology, Inc) for the extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy. Approval was based on data from ExteNET, a randomized, double-blind, placebo-controlled multicenter trial. Women with early-stage HER2-positive breast cancer and within two years of completing adjuvant trastuzumab were randomized to neratinib (n=1420) or placebo (n=1420) for one year. The primary endpoint was invasive disease-free survival (iDFS) defined as the time between randomization date to first occurrence of invasive recurrence (local/regional, ipsilateral or contralateral breast cancer), distance recurrence, or death from any cause, with two years and 28 days of follow up. The trial showed a statistically significant treatment effect favoring neratinib with a stratified hazard ratio of 0.66 (95% CI: 0.49, 0.90, p=0.008). Estimated iDFS rate at 2-years was 94.2% (95% CI: 92.6%, 95.4%) in patients treated with neratinib vs. 91.9% (95% CI: 90.2%, 93.2%) in those receiving placebo. Diarrhea was the most common adverse event (AE) with a 40% incidence of Grade 3 or 4 diarrhea and represents the most common AE leading to treatment discontinuation. Other frequent AEs (>10% incidence) were nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, and muscle spasms. Other than diarrhea, neratinib is associated with a low incidence of severe AEs; toxicities are generally reversible and manageable with dose interruptions, dose reductions, and/or standard medical care. This article summarizes FDA decision-making and data supporting the neratinib approval.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher

  3 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29523051
[Au] Autor:Gowarty JL; Herrington JD
[Ad] Address:Scott and White Medical Center-Temple, Temple, TX, USA.
[Ti] Title:Verapamil as a culprit of palbociclib toxicity.
[So] Source:J Oncol Pharm Pract;:1078155218761798, 2018 Jan 01.
[Is] ISSN:1477-092X
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:A promising drug, palbociclib, received accelerated approval as a first line treatment when used with the aromatase inhibitor, letrozole, for postmenopausal women with hormone receptor positive advanced or metastatic breast cancer. We report a case of a patient who presented with febrile neutropenia, grade 3 stomatitis with lip swelling, periorbital edema, and transaminitis while on palbociclib and verapamil. Labs normalized upon discontinuation of verapamil and our patient was able to continue treatment with palbociclib and letrozole. Verapamil's inhibition of both permeability-glycoprotein (P-gp) and CYP3A4 is suspected to have led to the adverse side effects seen in our patient.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180310
[Lr] Last revision date:180310
[St] Status:Publisher
[do] DOI:10.1177/1078155218761798

  4 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29505533
[Au] Autor:Asakura K; Yanai S; Nakamura S; Kawaski K; Eizuka M; Ishida K; Endo M; Sugai T; Migita K; Matsumoto T
[Ad] Address:Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University.
[Ti] Title:Familial Mediterranean fever mimicking Crohn disease: A case report.
[So] Source:Medicine (Baltimore);97(1):e9547, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Familial Mediterranean fever (FMF) is the most common form of autoinflammatory disease. We report a rare case of FMF with gastrointestinal lesions mimicking Crohn disease. PATIENT CONCERNS: A 21-year-old Japanese man was referred to our institution, complaining of refractory diarrhea and weight loss of 14 kg during the past two years. He had presented with recurrent fever, abdominal pain, anal fistula and stomatitis. His father and one of his brothers had ulcerative colitis. Colonoscopy revealed longitudinal ulcers in the terminal ileum and aphthous erosions in the colorectum. Esophagogastroduodenoscopy revealed multiple linear erosions in the gastric corpus and circular erosions in the duodenal second portion. Biopsy from these lesions failed to detect epithelioid cell granulomas. DIAGNOSES: Analysis of the genomic DNA revealed compound heterozygous mutations of E148Q/L110P in exon 2 of MEFV gene, suggesting a diagnosis of FMF. INTERVENTIONS: The patient was subsequently given 0.5 mg of colchicine per day. OUTCOMES: Follow-up colonoscopy 6 months later demonstrated that both the longitudinal ulcers in the terminal ileum and aphthous lesions in the colorectum had completely disappeared. LESSONS: Our case suggests that patients with FMF possibly manifest gastrointestinal lesions mimicking Crohn disease.
[Mh] MeSH terms primary: Crohn Disease/diagnosis
Familial Mediterranean Fever/diagnosis
[Mh] MeSH terms secundary: Colonoscopy
Diagnosis, Differential
Humans
Male
Young Adult
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009547

  5 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29385198
[Au] Autor:Wang J; Zhang T; Lu Y; Zhou G; Chen Q; Niu B
[Ad] Address:Shanghai Key Laboratory of Bio-Energy Crops, School of Life Sciences, Shanghai University, Shanghai, P. R. China.
[Ti] Title:Vesicular stomatitis forecasting based on Google Trends.
[So] Source:PLoS One;13(1):e0192141, 2018.
[Is] ISSN:1932-6203
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND: Vesicular stomatitis (VS) is an important viral disease of livestock. The main feature of VS is irregular blisters that occur on the lips, tongue, oral mucosa, hoof crown and nipple. Humans can also be infected with vesicular stomatitis and develop meningitis. This study analyses 2014 American VS outbreaks in order to accurately predict vesicular stomatitis outbreak trends. METHODS: American VS outbreaks data were collected from OIE. The data for VS keywords were obtained by inputting 24 disease-related keywords into Google Trends. After calculating the Pearson and Spearman correlation coefficients, it was found that there was a relationship between outbreaks and keywords derived from Google Trends. Finally, the predicted model was constructed based on qualitative classification and quantitative regression. RESULTS: For the regression model, the Pearson correlation coefficients between the predicted outbreaks and actual outbreaks are 0.953 and 0.948, respectively. For the qualitative classification model, we constructed five classification predictive models and chose the best classification predictive model as the result. The results showed, SN (sensitivity), SP (specificity) and ACC (prediction accuracy) values of the best classification predictive model are 78.52%,72.5% and 77.14%, respectively. CONCLUSION: This study applied Google search data to construct a qualitative classification model and a quantitative regression model. The results show that the method is effective and that these two models obtain more accurate forecast.
[Mh] MeSH terms primary: Internet
Livestock
Vesicular Stomatitis/epidemiology
[Mh] MeSH terms secundary: Animals
Disease Outbreaks
Forecasting
Ruminants
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:IM
[Da] Date of entry for processing:180201
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0192141

  6 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29519972
[Au] Autor:Koray M; Atalay B; Akgul S; Oguz FS; Mumcu G; Saruhanoglu A
[Ad] Address:Faculty of Dentistry, Department of Oral and Maxillofacial Surgery, Istanbul University, Capa, Fatih, Istanbul, Turkey.
[Ti] Title:Relationship between salivary calprotectin levels and recurrent aphthous stomatitis: A preliminary study.
[So] Source:Niger J Clin Pract;21(3):271-275, 2018 Mar.
[Is] ISSN:1119-3077
[Cp] Country of publication:India
[La] Language:eng
[Ab] Abstract:Aim: Recurrent aphthous stomatitis (RAS) is an inflammatory condition of the oral mucosa. The etiology of RAS remains unclear. Calprotectin is a major cytoplasmic protein contained in granulocytes, monocytes/macrophages and epithelial cells, and its level is increased body fluids in some inflammatory diseases. The aim is to determine the relationship between salivary calprotectin and RAS. Material and Methods: In the cross-sectional study, 67 patients with active lesions of RAS (F/M: 43/24, mean age: 30.27 ± 9.14 years) and 42 healthy controls (HC, F/M: 30/12, 30.54 ± 9.49 years) were included. Calprotectin levels were evaluated in unstimulated whole saliva samples by using the ELISA method in both groups. Results: Salivary calprotectin levels were significantly higher in RAS group (23.72 ± 4.28 mg/L) compared to the HC group (21.59 ± 4.27 mg/L) (P = 0.013). No significant relationship was found between calprotectin levels and age or gender in both groups (P >0.05). Conclusion: RAS is a very common inflammatory ulcerative condition of the oral cavity and its etiology is uncertain. Regarded as an inflammatory mechanism, releasing a high level of calprotectin in saliva has been suggested that it may play a role in pathogenesis of RAS.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process
[do] DOI:10.4103/njcp.njcp_23_17

  7 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29518389
[Au] Autor:Qian G; Hu X; Li G; Ding Y; Zhu L; Zheng H; Li M; Li Z; Pan J; Li Y; Li G; Yang C; Liu Y; Xie Y; Lv H
[Ad] Address:Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, Jiangsu Province, 215025, China. Electronic address: ghqian@suda.edu.cn.
[Ti] Title:Smurf1 restricts the antiviral function mediated by USP25 through promoting its ubiquitination and degradation.
[So] Source:Biochem Biophys Res Commun;, 2018 Mar 05.
[Is] ISSN:1090-2104
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Protein ubiquitination and deubiquitination enzymes are widely involved in innate immune responses. The ubiquitin specific protease 25 (USP25), a deubiquitinating enzyme, has been demonstrated to play an important role in virus infection and immunity. However, how USP25 is degraded and regulated by E3 ubiquitin ligases remains poorly understood. Here, we identified Smad ubiquitin regulatory factor 1(Smurf1) as a first novel E3 ubiquitin ligase of USP25. Smurf1 overexpression decreases USP25 protein turnover, and the E3 ligase enzymatic activity of Smurf1 is required for USP25 degradation. Additionally, Smurf1-mediated degradation of USP25 is via promoting the K48-linkage polyubiquitination of USP25 in an ubiquitin proteasome dependent pathway. Importantly, USP25 overexpression restricts vesicular stomatitis virus (VSV) replication and the restriction of VSV replication by USP25 is enhanced in Smurf1 stable knock down cells. Therefore, our study firstly identified that Smurf1 negatively regulated the antiviral function mediated by USP25. Our findings revealed a previously unrecognized role of Smurf1 acting on USP25 and also their roles in the regulation of VSV replications.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher

  8 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29494396
[Au] Autor:Stoopler ET; Brod BA; Sollecito TP
[Ti] Title:Allergic Contact Stomatitis Associated With Sweet Vermouth.
[So] Source:Dermatitis;29(2):89-91, 2018 Mar/Apr.
[Is] ISSN:2162-5220
[Cp] Country of publication:United States
[La] Language:eng
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1097/DER.0000000000000353

  9 / 22976 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29458673
[Au] Autor:Morse DJ; Wilson MJ; Wei X; Lewis MAO; Bradshaw DJ; Murdoch C; Williams DW
[Ad] Address:1​Oral and Biomedical Sciences, School of Dentistry, Cardiff University, Cardiff, UK.
[Ti] Title:Denture-associated biofilm infection in three-dimensional oral mucosal tissue models.
[So] Source:J Med Microbiol;67(3):364-375, 2018 Mar.
[Is] ISSN:1473-5644
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:PURPOSE: In vitro analyses of virulence, pathogenicity and associated host cell responses are important components in the study of biofilm infections. The Candida-related infection, denture-associated oral candidosis, affects up to 60 % of denture wearers and manifests as inflammation of palatal tissues contacting the denture-fitting surface. Commercially available three-dimensional tissue models can be used to study infection, but their use is limited for many academic research institutions, primarily because of the substantial purchase costs. The aim of this study was to develop and evaluate the use of in vitro tissue models to assess infections by biofilms on acrylic surfaces through tissue damage and Candida albicans virulence gene expression. METHODOLOGY: In vitro models were compared against commercially available tissue equivalents (keratinocyte-only, SkinEthic; full-thickness, MatTek Corporation). An in vitro keratinocyte-only tissue was produced using a cancer-derived cell line, TR146, and a full-thickness model incorporating primary fibroblasts and immortalised normal oral keratinocytes was also generated. The in vitro full-thickness tissues incorporated keratinocytes and fibroblasts, and have potential for future further development and analysis. RESULTS: Following polymicrobial infection with biofilms on acrylic surfaces, both in-house developed models were shown to provide equivalent results to the SkinEthic and MatTek models in terms of tissue damage: a significant (P<0.05) increase in LDH activity for mixed species biofilms compared to uninfected control, and no significant difference (P>0.05) in the expression of most C. albicans virulence genes when comparing tissue models of the same type. CONCLUSION: Our results confirm the feasibility and suitability of using these alternative in vitro tissue models for such analyses.
[Mh] MeSH terms primary: Biofilms/growth & development
Candidiasis, Oral/microbiology
Dentures/microbiology
Host-Pathogen Interactions
Mouth Mucosa/microbiology
[Mh] MeSH terms secundary: Candida albicans/genetics
Candida albicans/pathogenicity
Candida albicans/physiology
Cell Line
Coinfection/microbiology
Fibroblasts/microbiology
Humans
Keratinocytes/microbiology
Polymethyl Methacrylate
Stomatitis, Denture
Virulence
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:9011-14-7 (Polymethyl Methacrylate)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:180221
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000677

  10 / 22976 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29440426
[Au] Autor:Franz KM; Neidermyer WJ; Tan YJ; Whelan SPJ; Kagan JC
[Ad] Address:Division of Gastroenterology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115.
[Ti] Title:STING-dependent translation inhibition restricts RNA virus replication.
[So] Source:Proc Natl Acad Sci U S A;115(9):E2058-E2067, 2018 Feb 27.
[Is] ISSN:1091-6490
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:In mammalian cells, IFN responses that occur during RNA and DNA virus infections are activated by distinct signaling pathways. The RIG-I-like-receptors (RLRs) bind viral RNA and engage the adaptor MAVS (mitochondrial antiviral signaling) to promote IFN expression, whereas cGAS (cGMP-AMP synthase) binds viral DNA and activates an analogous pathway via the protein STING (stimulator of IFN genes). In this study, we confirm that STING is not necessary to induce IFN expression during RNA virus infection but also find that STING is required to restrict the replication of diverse RNA viruses. The antiviral activities of STING were not linked to its ability to regulate basal expression of IFN-stimulated genes, activate transcription, or autophagy. Using vesicular stomatitis virus as a model, we identified a requirement of STING to inhibit translation during infection and upon transfection of synthetic RLR ligands. This inhibition occurs at the level of translation initiation and restricts the production of viral and host proteins. The inability to restrict translation rendered STING-deficient cells 100 times more likely to support productive viral infections than wild-type counterparts. Genetic analysis linked RNA sensing by RLRs to STING-dependent translation inhibition, independent of MAVS. Thus, STING has dual functions in host defense, regulating protein synthesis to prevent RNA virus infection and regulating IFN expression to restrict DNA viruses.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Data-Review
[do] DOI:10.1073/pnas.1716937115


page 1 of 2298 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information